Indo US Bio-Tech Ltd.

Indo US Bio-Tech Ltd.

67.92
INR
-0.05
(-0.07%)
5.70EPS
15.30P/E
1.75BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
10.17
13.44
13.08
16.83
28.66
25.08
27.3
27.54
40.9
32.01
36.32
51.78
55.08
56.04
Basic EPS, GAAP
0.18
0.34
0.25
0.27
1.41
1.48
1.74
3.36
4.14
3.75
4.11
8.11
6.54
5.7
Free Cash Flow per Basic Share
0.18
-0.02
-1.85
-0.07
-1.3
-3.17
-0.85
-1.23
-1.03
-0.67
-0.19
0.28
-7.48
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.12
- -
- -
0.25
- -
- -
Book Value per Share
2.04
2.82
3.17
3.4
4.81
9.55
11.29
14.65
21
27.18
31.29
39.16
46.15
- -
Tangible Book Value per Share
2.04
2.82
3.17
3.4
4.81
9.55
11.29
14.65
21
27.18
31.29
39.16
46.15
- -
Basic Weighted Avg Shares
15
15
15
15
10
14
15
15
12
19
20
20
20
20
Sales/Revenue/Turnover
148
196
190
245
294
353
398
401
501
617
728
1,038
1,104
1,127
Operating Margin (%)
1.92
2.84
1.95
4.72
8.71
9.07
9.48
12.75
13.31
13.91
14.23
17.34
14.7
12.9
Depreciation Expense
1
1
1
1
2
2
2
3
4
8
8
11
9
10
Net Income, GAAP
3
5
4
4
14
21
25
49
51
72
82
163
131
115
Effective Tax Rate (%)
- -
- -
- -
24.08
28.98
25.7
11.49
- -
4.67
1.98
6.29
1.59
5.73
5.91
Profit Margin (%)
1.75
2.53
1.89
1.62
4.92
5.91
6.37
12.22
10.11
11.73
11.31
15.67
11.88
10.17
Working Capital
8
18
18
23
48
125
152
200
346
476
542
704
812
- -
LT Debt
- -
5
2
3
14
7
8
35
37
17
28
29
10
- -
Total Equity
21
29
33
35
49
139
164
213
385
545
627
785
925
- -
Return on Invested Capital (%)
- -
- -
- -
10.3
18.38
14.97
14.68
- -
15.02
14.86
13.87
21.28
13.95
- -
Return on Capital (%)
- -
- -
- -
10.76
19.49
14.82
14.31
- -
14.61
14.21
13.36
20.75
13.58
- -
Return on Common Equity (%)
13.19
19.83
11.69
11.74
34.36
22.16
16.7
25.94
16.92
15.57
14.06
23.03
15.34
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
361
- -
LT Borrowings
- -
10
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
20
Market Capitalization
2,450
1,963
1,749

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,207
- -
Cash, Cash Equivalents & STI
- -
69
- -
Accounts Receivable, Net
- -
138
- -
Inventories
- -
1,000
- -
Total Current Liabilities
- -
395
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
361
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
45.83%
36.01%
17.85%
Free Cash Flow
-180.19%
-626.07%
-2,790.01%
Net Income, GAAP
57.29%
27.65%
-19.33%
Sales/Revenue/Turnover
19.72%
23%
6.36%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
247
222
236
228
1,038
2026
308
308
228
260
1,104
2027
330
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.58
2.16
2.52
1.49
8.11
2026
2.35
1.72
1.49
0.98
6.54
2027
1.51
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
0.25
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Jagdishbhai D. Ajudia
Full Time Employees
883
Sector
Process industries
Industry
Agricultural commodities/Milling
Address
309, Shanti Mall Ahmedabad GU India 380061
IPO Date
May 11, 2018
Business
Indo US Bio-Tech Ltd engages in the research, development, breeding, production, processing, packing and marketing of hybrid and open-pollinated varieties of agricultural seeds, including vegetable, cereal, pulse, spice and oil seeds; offers seed testing, soil and water testing services; and maintains an in-house DSIR-recognized R&D unit in Gujarat focused on developing high-performing germplasm varieties such as those marketed under brands like INDO-US 955 and INDO-US 936. The company, originally incorporated in 2004 as Pollucid Bio-Tech Private Limited and listed publicly since 2018, is headquartered at 309 Shanti Mall, Satadhar Cross Road, Ahmedabad, Gujarat, India, and operates seed processing plants in Gujarat with additional custom facilities across India to support a nationwide network of over 2,500 distributors and dealers serving more than 100,000 farmer customers. It holds ISO 9001-2008 certification and collaborates with entities like the National Seeds Corporation, HIL India and various universities for breeder seed commercialization. Recent developments include participation in the APSA Seed Congress 2025 in Mumbai from November 17-20, board approval of unaudited financial results for the quarter and half-year ended September 30, 2025 showing revenue of Rs 119 crore and profit of Rs 16.9 crore, and sustained profit growth of 45% CAGR over the last five years amid improved debtor days and sales expansion.